Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Change in Account Payables (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Change in Account Payables readings, the most recent being -$1.3 million for Q4 2025.

  • Quarterly Change in Account Payables fell 415.66% to -$1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$512000.0 through Dec 2025, down 39.51% year-over-year, with the annual reading at -$512000.0 for FY2025, 39.51% down from the prior year.
  • Change in Account Payables hit -$1.3 million in Q4 2025 for Terns Pharmaceuticals, down from $97000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $2.8 million in Q2 2023 and bottomed at -$2.2 million in Q3 2023.
  • Average Change in Account Payables over 5 years is $63750.0, with a median of -$17500.0 recorded in 2021.
  • The largest annual shift saw Change in Account Payables surged 1586.67% in 2021 before it crashed 415.66% in 2025.
  • Terns Pharmaceuticals' Change in Account Payables stood at $506000.0 in 2021, then tumbled by 193.08% to -$471000.0 in 2022, then crashed by 71.97% to -$810000.0 in 2023, then surged by 151.23% to $415000.0 in 2024, then crashed by 415.66% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Change in Account Payables are -$1.3 million (Q4 2025), $97000.0 (Q3 2025), and $71000.0 (Q2 2025).